| Literature DB >> 22046512 |
George A Kelley1, Kristi S Kelley, Dina L Jones.
Abstract
Fibromyalgia is a major public health problem affecting an estimated 200 to 400 million people worldwide. The purpose of this study was to use the meta-analytic approach to determine the efficacy and effectiveness of randomized controlled exercise intervention trials (aerobic, strength training, or both) on tender points (TPs) in adults with fibromyalgia. Using random effects models and 95% confidence intervals (CI), a statistically significant reduction in TPs was observed based on per-protocol analyses (8 studies representing 322 participants) but not intention-to-treat analyses (5 studies representing 338 participants) (per-protocol, g, -0.68, 95% CI, -1.16, -0.20; intention-to-treat, g, -0.24, 95% CI, -0.62, 0.15). Changes were equivalent to relative reductions of 10.9% and 6.9%, respectively, for per-protocol and intention-to-treat analyses. It was concluded that exercise is efficacious for reducing TPs in women with FM. However, a need exists for additional well-designed and reported studies on this topic.Entities:
Year: 2011 PMID: 22046512 PMCID: PMC3195857 DOI: 10.1155/2011/125485
Source DB: PubMed Journal: Arthritis ISSN: 2090-1992
Figure 1Flow diagram for the selection of studies. Stepwise procedures used for the selection of tender point studies. Note that RCT means randomized controlled trial.
General characteristics of included studies.
| Reference |
| Age (Years) | Gender (F/M) | FM symptoms (Years) | Exercise intervention | Tender point assessment |
|---|---|---|---|---|---|---|
| Gowans et al. [ | Ex: 27 | Ex: 44.6 ± 8.7 | F (88%)/M | Ex: 9.6 ± 8.6 | 23 weeks supervised, facility-based aerobic exercise, 3x/wk, 20 min/day, 60%–75% MHR; compliance, 67%. | Sum of up to 18 TP; assessor blinded to group assignment |
|
| ||||||
| Gusi et al. [ | Ex: 17 | Ex: 51 ± 10 | F | Ex: 24 ± 9 | 12 weeks supervised pool-based exercise, 3x/wk; aerobic (20 min/day, 65%–75% MHR, strengthening (20 min/day, 4 sets, 10 reps); compliance >94% | Sum of up to 18 TP |
|
| ||||||
| Hakkinen et al. [ | Ex: 11 | Ex: 39 ± 6 | F | Ex: 12 ± 4 | 17 weeks supervised strength training, 6–8 ex, 2x/wk, 5–20 reps, 40%–80% 1RM | Sum of up to 18 TP |
|
| ||||||
| King et al. [ | Ex: 46 | Ex: 45.2 ± 9.4 | F | Ex: 7.8 ± 6.1 | 12 weeks supervised, facility-based aerobic ex, 3x/wk, 10–40 min/day, 75% MHR | Sum of up to 18 TP; both assessors blinded to group assignment |
|
| ||||||
| Kingsley et al. [ | Ex: 15 | Ex: 45 ± 9 | F | Ex: 9 ± 10 | 12 weeks strength training, 11 ex, 2x/wk, 1 set, 8–12 reps, 40%–80% 1RM | Total number of TP and total myalgic score; assessor blinded to group assignment |
|
| ||||||
| Munguía-Izquierdo and Legaz-Arrese [ | Ex: 29 | Ex: 50 ± 7 | F | Ex: 14 ± 10 | 16 weeks supervised, facility-based ex, 3x/wk; strengthening (1–3 sets, 8–15 reps, 8–10 ex); aerobic (20–30 min, 50%–80% MHR); compliance ≥75% | Sum of up to 18 TP |
|
| ||||||
| Schachter et al. [ | Ex (sb): 56 | Ex (sb): 41.9 ± 8.6 | F | Ex (sb): 8.6 ± 6.0 | 16 weeks home-based, low-impact aerobic ex; short bout, 2x/day, 3x/wk, 5–15 min/session, 40%–75% HRR; long bout, 1x/day, 3x/wk, 10–30 min/session, 40%–75% HRR | Mean number of TP and mean myalgic score using a dolorimeter; assessor blinded to group assignment |
|
| ||||||
| Valkeinen et al. [ | Ex: 13 | Ex: 60 ± 2 | F | NR | 21 weeks supervised strength training, 6–7 ex, 2x/wk, 5–20 reps, 40%–80% 1RM, 97% compliance | Sum of up to 18 TP |
|
| ||||||
| Wigers et al. [ | Ex: 20 | Ex: 43 ± 9 | F (90%)/M | Ex: 9.0 ± 5 | 14 weeks supervised aerobic exercise, 3x/wk, 18–20 min/day, 60%–70% MHR | Mean number of TP using dolorimetry |
Notes: Description of groups and subjects from each study limited to those that met the inclusion criteria; N, Initial number of subjects as reported by authors; age reported as mean () ± standard deviation (SD); F, females; M, males; Ex, Exercise; Con, Control; FM, fibromyalgia; MHR, maximum heart rate; 1RM, one-repetition maximum; HRR, heart rate reserve; lb, long bout; sb, short bout; min, minutes; wk, week; reps, repetitions; TP, tender points; NR, not reported.
Figure 2Risk of bias assessment. Percentage of studies classified as having a low, high, or unclear risk of bias for the seven listed categories. Note that TP means tender points.
Baseline characteristics of exercise and control groups.
| Exercise | Control | Difference | Heterogeneity | Inconsistency | |||||
|---|---|---|---|---|---|---|---|---|---|
| Variable |
|
| Mdn (IQR) |
|
| Mdn (IQR) |
|
|
|
| Age (years) | 10 | 46.1 ± 6.1 | 45 (9) | 9 | 47.3 ± 6.0 | 47 (6) | −0.5 (−2.1, 1.0) | 13.5 (0.14) | 33.1% (0, 68.1) |
| FM Symptoms (years) | 8 | 11.4 ± 5.1 | 9 (4) | 8 | 11.2 ± 3.8 | 10 (5) | 0.04 (−1.2, 1.2) | 5.1 (0.65) | 0% (0, 56.0%) |
| FM Diagnosis (years) | 4 | 4.2 ± 2.3 | 3 (4) | 3 | 5.1 ± 2.2 | 4 (4) | −0.5 (−1.3, 0.3) | 1.4 (0.71) | 0% (0%, 72.0%) |
Notes: FM, fibromyalgia syndrome; N, number of groups reporting data; , mean ± standard deviation; Mdn (IQR), median and interquartile range; (95% CI), mean and 95% confidence intervals; Q (p), heterogeneity statistic and alpha value; I 2 (95% CI), percent inconsistency and 95% confidence interval.
TP results.
| Variable | Studies (#) |
|
|
|
|---|---|---|---|---|
| PP Analysis | ||||
| Overall | 8 | −0.68 (−1.16, −0.20)* | 28.6 (<0.0001)** | 75.5% (50.9%, 87.8%) |
| Type of training | ||||
| Aerobic | 4 | −0.44 (−1.04, 0.16) | 11.2 (0.01)** | 73.2% (24.7%, 50.5%) |
| Strength | 2 | −1.13 (−1.73, −0.53)* | 0.5 (0.47) | 0% |
| Both | 2 | −0.75 (−2.22, 0.71) | 10.8 (0.001)** | 90.7% (66.7%, 97.4%) |
| Sedentary prior to enrollment | ||||
| Yes | 5 | −0.67 (−1.23, −0.08)* | 16.6 (0.002)** | 76.0% (41.2%, 90.2%) |
| Unclear | 3 | −0.71 (−1.73, 0.31) | 11.8 (0.003)** | 83.1% (48.6%, 94.4%) |
|
| ||||
| ITT Analysis | ||||
| Overall | 4 | −0.24 (−0.62, 0.15) | 10.1 (0.04)** | 60.6% (0%, 85.2%) |
| Type of training | ||||
| Aerobic | 4 | −0.24 (−0.71, 0.22) | 10.1 (0.02)** | 70.3% (37.4%, 93.7%) |
| Strength | 1 | 0.25 (−0.96, 0.46) | — | — |
| Both | — | — | — | — |
| Sedentary prior to enrollment | ||||
| Yes | 2 | −0.14 (−0.47, 0.20) | 0.62 (0.43) | 0% |
| Unclear | 3 | −0.33 (−1.1, 0.42) | 9.4 (0.009)** | 78.8% (32.2%, 93.4%) |
Notes: PP, per-protocol; ITT, intention-to-treat; g (95% CI), Hedge's g and 95% confidence intervals; Q (p), heterogeneity statistic and alpha value; I 2 (95% CI), percent inconsistency and 95% confidence interval; —, insufficient data to calculate; *statistically significant within-group difference because 95% confidence intervals do not include 0; **statistically significant heterogeneity (p ≤ 0.10).
Figure 3Forest plot for changes in tender points according to per-protocol analysis. The black squares represent the standardized mean difference (Hedge's g), while the left and right extremes of the squares represent the corresponding 95% confidence intervals. The middle of the black diamond represents the overall standardized mean difference (Hedge's g), while the left and right extremes of the diamond represent the corresponding 95% confidence intervals.
Figure 4Forest plot for changes in tender points according to intention-to-treat analysis. The black squares represent the standardized mean difference (Hedge's g), while the left and right extremes of the squares represent the corresponding 95% confidence intervals. The middle of the black diamond represents the overall standardized mean difference (Hedge's g), while the left and right extremes of the diamond represent the corresponding 95% confidence intervals.